• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1例肺静脉闭塞病合并肺栓塞患者的病例报告:是否抗凝?

A case report of PVOD patient combined with pulmonary embolism: Anticoagulation or not?

作者信息

Yuan Xiaoling, Hou Xianghe, Guo Weihong, Jiang Haiming, Zheng Junmeng, Paudyal Stuti, Lyu Yanhua

机构信息

Respiratory Department Pathology Department Cardiothoracic Surgery, People's Hospital of Zhongshan City, Zhongshan City Medical Intern, Sun Yat-Sen University, China.

出版信息

Medicine (Baltimore). 2017 Mar;96(13):e6507. doi: 10.1097/MD.0000000000006507.

DOI:10.1097/MD.0000000000006507
PMID:28353604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5380288/
Abstract

RATIONALE

Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary arterial hypertension (PAH). Oral anticoagulation is confined to patients with idiopathic PAH (IPAH), but no oral anticoagulation has been recommended for PVOD, because occult pulmonary hemorrhage was a common finding in PVOD.

PATIENT CONCERNS

We report a case of PVOD, who was misdiagnosed as IPAH for 5 years with worsening dyspnea and two episodes of pulmonary embolism (PE).

DIAGNOSES

He was confirmed as PVOD combined with PE by biopsy of the explanted lung specimen.

INTERVENTIONS

He took oral anticoagulation, warfarin, to treat his first-time PE in July 2010, and his disease was kept stable for about 4 years, until he discontinued the anticoagulation therapy by himself sometime in 2014. Later on, a life-threatening PE recurred in January 2015, so he resumed the anticoagulation therapy.

OUTCOMES

Fortunately, the bilateral sequential lung transplantation that was performed in July 2015 in time saved his life. He has been living well without dyspnea and the echocardiography showed the normalizations of the once increased pulmonary arterial pressure and the once enlarged right ventricle of his heart. In addition, to the best of my knowledge, he was the first PVOD patient receiving lung transplantation in China.

LESSONS

We recommend that PVOD patients combined with PE should be treated with anticoagulation therapy indefinitely to prevent the recurrence of life-threatening PE until they get a chance for lung transplantation.

摘要

理论依据

肺静脉闭塞性疾病(PVOD)是一种罕见的肺动脉高压(PAH)形式。口服抗凝治疗仅限于特发性PAH(IPAH)患者,但PVOD患者未被推荐使用口服抗凝治疗,因为隐匿性肺出血在PVOD中是常见表现。

患者情况

我们报告一例PVOD患者,该患者被误诊为IPAH达5年,伴有进行性加重的呼吸困难和两次肺栓塞(PE)发作。

诊断

通过对切除的肺标本进行活检,确诊为PVOD合并PE。

干预措施

他于2010年7月开始口服抗凝药物华法林治疗首次发作的PE,病情保持稳定约4年,直到2014年某个时候他自行停用抗凝治疗。后来,2015年1月再次发生危及生命的PE,于是他重新开始抗凝治疗。

结果

幸运的是,2015年7月及时进行的双侧序贯肺移植挽救了他的生命。他现在生活良好,没有呼吸困难,超声心动图显示曾经升高的肺动脉压和曾经扩大的右心室已恢复正常。此外,据我所知,他是中国首例接受肺移植的PVOD患者。

经验教训

我们建议,PVOD合并PE的患者应无限期接受抗凝治疗,以预防危及生命的PE复发,直到他们有机会接受肺移植。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f0/5380288/73c6743df64c/medi-96-e6507-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f0/5380288/73c6743df64c/medi-96-e6507-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11f0/5380288/73c6743df64c/medi-96-e6507-g001.jpg

相似文献

1
A case report of PVOD patient combined with pulmonary embolism: Anticoagulation or not?1例肺静脉闭塞病合并肺栓塞患者的病例报告:是否抗凝?
Medicine (Baltimore). 2017 Mar;96(13):e6507. doi: 10.1097/MD.0000000000006507.
2
Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients: A case report.2 例肺静脉闭塞病患者对肺动脉高压靶向治疗有良好反应:病例报告。
Medicine (Baltimore). 2021 Oct 15;100(41):e27334. doi: 10.1097/MD.0000000000027334.
3
Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?肺静脉闭塞性疾病的靶向治疗:是否需要重新思考?
BMC Pulm Med. 2019 Dec 19;19(1):257. doi: 10.1186/s12890-019-1031-3.
4
Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.肺静脉闭塞病:24例经组织学确诊病例的临床、功能、放射学及血流动力学特征与转归
Medicine (Baltimore). 2008 Jul;87(4):220-233. doi: 10.1097/MD.0b013e31818193bb.
5
Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences.特发性肺动脉高压与肺静脉闭塞病:异同点
Semin Respir Crit Care Med. 2009 Aug;30(4):411-20. doi: 10.1055/s-0029-1233310. Epub 2009 Jul 24.
6
Pulmonary veno-occlusive disease as a cause of severe pulmonary hypertension in a dog.肺静脉闭塞性疾病致犬重度肺动脉高压
Acta Vet Scand. 2018 Dec 5;60(1):78. doi: 10.1186/s13028-018-0433-1.
7
Anesthesia for pulmonary veno-occlusive disease: the dilemma and what we should know as anesthesiologists: A case report.肺静脉闭塞病的麻醉:困境以及作为麻醉医生我们应该了解的内容:一例病例报告
Medicine (Baltimore). 2020 Jul 24;99(30):e21517. doi: 10.1097/MD.0000000000021517.
8
[Pulmonary veno-occlusive disease - a rare form of pulmonary arterial hypertension].[肺静脉闭塞病——一种罕见的肺动脉高压形式]
Dtsch Med Wochenschr. 2008 Oct;133 Suppl 6:S212-4. doi: 10.1055/s-0028-1091242. Epub 2008 Sep 23.
9
Dual-energy CT lung perfusion characteristics in pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis (PVOD/PCH): preliminary experience in 63 patients.双能 CT 肺灌注特征在肺动脉高压 (PAH) 和肺静脉闭塞性疾病和/或肺毛细血管血管瘤病 (PVOD/PCH) 中的应用:63 例患者的初步经验。
Eur Radiol. 2022 Jul;32(7):4574-4586. doi: 10.1007/s00330-022-08577-x. Epub 2022 Mar 14.
10
Pulmonary veno-occlusive disease: a rare cause of pulmonary hypertension in systemic sclerosis. Case presentation and review of the literature .肺静脉闭塞病:系统性硬化症中肺动脉高压的罕见病因。病例报告及文献复习
Rom J Intern Med. 2015 Apr-Jun;53(2):175-83. doi: 10.1515/rjim-2015-0024.

引用本文的文献

1
Pulmonary Veno-Occlusive Disease: A Rare Cause of Pulmonary Hypertension.肺静脉闭塞病:肺动脉高压的罕见病因
J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619840375. doi: 10.1177/2324709619840375.

本文引用的文献

1
EIF2AK4 mutation in pulmonary veno-occlusive disease: A case report and review of the literature.肺静脉闭塞病中的EIF2AK4突变:一例报告并文献复习
Medicine (Baltimore). 2016 Sep;95(39):e5030. doi: 10.1097/MD.0000000000005030.
2
Pulmonary veno-occlusive disease.肺静脉闭塞病。
Eur Respir J. 2016 May;47(5):1518-34. doi: 10.1183/13993003.00026-2016. Epub 2016 Mar 23.
3
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
2015 ESC/ERS 肺动脉高压诊断与治疗指南:欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)肺动脉高压诊断与治疗工作组制定:该指南得到了欧洲儿科和先天性心脏病协会(AEPC)以及国际心肺移植学会(ISHLT)的认可。
Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29.
4
EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension.EIF2AK4 突变导致肺静脉闭塞性疾病,这是一种肺动脉高压的隐性形式。
Nat Genet. 2014 Jan;46(1):65-9. doi: 10.1038/ng.2844. Epub 2013 Dec 1.
5
Pulmonary embolism: risk assessment and management.肺栓塞:风险评估与管理。
Eur Heart J. 2012 Dec;33(24):3014-22. doi: 10.1093/eurheartj/ehs258. Epub 2012 Sep 7.
6
[Clinical characteristics and survival of patients with pulmonary veno-occlusive disease].[肺静脉闭塞病患者的临床特征与生存情况]
Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Oct;39(10):896-900.
7
Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences.特发性肺动脉高压与肺静脉闭塞病:异同点
Semin Respir Crit Care Med. 2009 Aug;30(4):411-20. doi: 10.1055/s-0029-1233310. Epub 2009 Jul 24.
8
Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease.在肺静脉闭塞性疾病中,谨慎的依前列醇治疗是肺移植的安全桥接。
Eur Respir J. 2009 Dec;34(6):1348-56. doi: 10.1183/09031936.00017809. Epub 2009 Jun 18.
9
Pulmonary veno-occlusive disease.肺静脉闭塞病
Eur Respir J. 2009 Jan;33(1):189-200. doi: 10.1183/09031936.00090608.
10
Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.肺静脉闭塞病:24例经组织学确诊病例的临床、功能、放射学及血流动力学特征与转归
Medicine (Baltimore). 2008 Jul;87(4):220-233. doi: 10.1097/MD.0b013e31818193bb.